As research advances, the CD19/CD20/CD22 triple CAR represents a promising next step in optimizing CAR T-cell therapy for CLL, with the potential to achieve deeper and more lasting clinical responses. This evidence concerns the gene CD19 and B-cell chronic lymphocytic leukemia.